Alterity Therapeutics Ltd.

As of June 30, 2026, Alterity Therapeutics Ltd. carries a market capitalization of 125.07M, placing it among publicly traded companies globally. Its enterprise value stands at 87.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Alterity Therapeutics Ltd.'s next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Alterity Therapeutics Ltd. has 217.51M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Alterity Therapeutics Ltd. maintains a current ratio of 14.52, meaning it holds 14.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Alterity Therapeutics Ltd.'s stock has declined approximately 99.12% over the past 52 weeks. The 50-day moving average sits at 0.43, while the 200-day moving average is 11.56.

As of June 30, 2026, Alterity Therapeutics Ltd. holds 37.32M in cash and equivalents against 193,465.00 in total debt, resulting in a net debt position of -37.32M. Total book value stands at 42.72M, with working capital of 42.67M providing operational flexibility.

Over the twelve months ended June 30, 2026, Alterity Therapeutics Ltd. paid dividends of - - per share. Total shareholder yield is negative at -20.10, meaning Alterity Therapeutics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Alterity Therapeutics Ltd.'s most recent stock split took place on June 12, 2026 with a 50:1 split ratio.